TETEC AG

What TETEC AG does

TETEC AG is a German Aktiengesellschaft headquartered in Reutlingen that develops and manufactures autologous cell-based therapies for the biological regeneration of cartilage defects in the human musculoskeletal system. The company was founded in 2000 as a spin-off from the Natural and Medical Sciences Institute and the Berufsgenossenschaftliche Unfallklinik Tübingen, and has accumulated over 20 years of clinical experience with more than 30,000 individual products manufactured and over 7,000 Injectable MACT procedures performed in Germany since 2008.

The core product portfolio consists of two matrix-associated autologous chondrocyte transplantation (MACT) systems: NOVOCART 3D, a biphasic collagen matrix seeded with the patient's own chondrocytes for focal cartilage defects of 2–10 cm²; and NOVOCART Inject, a PEG-albumin-hyaluronic acid hydrogel-based injectable system that self-sets in 1–3 minutes and supports minimally invasive arthroscopic delivery for defects of 2–12 cm². Manufacturing takes place in GMP-certified cleanrooms using closed isolator systems under Paul-Ehrlich-Institut oversight, with quantitative PCR-based cell and molecular biology quality control for each product. An EMA centralized approval application for the gel-based ATMP was submitted in December 2023.

TETEC monetizes through one-time per-patient sales of its ATMP products to hospitals, orthopedic clinics, and certified treatment centers in Germany (reimbursed in part by the German public health insurance system, GKV), supplemented by contract development and manufacturing services for other ATMP developers (TETEC CDMO, now rebranded as Octane CDMO following the 2024 acquisition). The company serves orthopedic surgeons, sports medicine physicians, and patients with focal knee cartilage defects, using a direct enterprise field sales motion supplemented by conference participation, a DocCheck-secured physician portal, and dedicated customer service and tissue harvesting teams. In June 2024, TETEC was acquired by Octane Biotherapeutics (BioTx), part of Canada's Octane Medical Group, alongside Aesculap Biologics LLC in the United States, with planned integration of Octane's Cocoon automated bioreactor for scalable cell therapy production.

Name

TETEC AG

Legal name

TETEC AG

Website

https://tetec-ag.de

Company type

Private

Founded year

2000

Operating status

Operating

Short description

TETEC AG is a Reutlingen-based German biotechnology company that develops and manufactures autologous cell-based MACT cartilage regeneration products (NOVOCART 3D and NOVOCART Inject) and CDMO services, selling to hospitals and orthopedic clinics treating patients with focal knee cartilage defects.

Ownership category

akta.pro rank

Product category

Orthobiologics and Cell-Based Cartilage Regeneration Therapies

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Autologous chondrocyte transplantation
• Cartilage regeneration therapy
• Cell-based tissue engineering
• Advanced therapy medicinal products
• Orthobiologics manufacturing

Headquarters

HQ city

Reutlingen

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. ATMP Product Sales (NOVOCART 3D and NOVOCART Inject): Sale of cell-based tissue engineering products for cartilage regeneration. Products are manufactured individually for each patient and sold to hospitals and orthopedic clinics. Revenue from product sales to healthcare providers.
2. CDMO Services (via Octane CDMO): Contract development and manufacturing services for other ATMP developers, including process translation to GMP environment, clinical specimen manufacturing, clinical trial coordination, and regulatory approval support.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

TETEC AG develops and manufactures autologous cell-based tissue engineering products for the biological regeneration of focal cartilage defects in the human musculoskeletal system. Its core offerings are two matrix-associated autologous chondrocyte transplantation (MACT) products — NOVOCART 3D (collagen matrix scaffold) and NOVOCART Inject (injectable hydrogel) — individually manufactured for each patient and sold to hospitals and orthopedic clinics. The company also provides CDMO services for Advanced Therapy Medicinal Product (ATMP) developers.

Product overview

TETEC AG offers two distinct autologous cell-based cartilage regeneration products: NOVOCART 3D (a biphasic collagen scaffold-based MACT system for defects 2-10 cm²) and NOVOCART Inject (an injectable hydrogel-based MACT for defects 2-12 cm²). Both products use the patient's own cultivated chondrocytes to support cartilage repair in focal knee defects. The company also operates TETEC CDMO (now rebranded as Octane CDMO), providing contract development and manufacturing services for ATMP developers. The product portfolio is complemented by the planned integration of Octane's Cocoon automated bioreactor for scalable cell therapy production.

Differentiator

Problem solved

Functional benefit

Products and services

• NOVOCART 3D A biphasic collagen matrix scaffold seeded with the patient's own cartilage cells (chondrocytes), used for matrix-associated autologous chondrocyte transplantation (MACT) to treat focal knee cartilage defects ranging from 2 cm² to 10 cm². Sold to hospitals and orthopedic clinics and individually manufactured for each patient.
• NOVOCART Inject An injectable matrix-associated autologous chondrocyte transplantation product combining the patient's cartilage cells with a PEG-albumin-hyaluronic acid hydrogel that self-sets in 1–3 minutes, securing the graft in place. Indicated for defects from 2 cm² to 12 cm² and delivered arthroscopically with operating times of 15–40 minutes. Sold to hospitals and orthopedic clinics.
• TETEC CDMO (now Octane CDMO) Contract development and manufacturing organization services for Advanced Therapy Medicinal Product (ATMP) developers, including process translation to GMP environment, clinical specimen manufacturing, clinical trial coordination, regulatory approvals, and ATMP registration support. Delivered from the Reutlingen GMP-certified cleanroom facility.

Quantifiable outcome

• Over 90% success rate reported in 10+ year follow-up studies for MACT procedures
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, former and minor.

• Octane Medical GroupcoreStrategic or Co-development Partner · 5 June 2024Octane Medical Group acquired TETEC AG in June 2024 as part of acquiring B. Braun's global orthobiologics business. TETEC became part of Octane Biotherapeutics (BioTx), combining TETEC's ATMP expertise with Octane's automated bioreactor technology (Cocoon). This integration enables transition from manual to automated cell production, potentially reducing costs while increasing quality and scalability.
• B. BraunformerOthers · 5 June 2024B. Braun was the former parent company of TETEC through Aesculap Inc. TETEC originated from the biologics business of Aesculap. B. Braun sold its orthobiologics business to Octane Medical Group in June 2024. Dr. Jens von Lackum stated this sale was part of B. Braun's strategic focus on the Operating Room.
• Natural and Medical Sciences InstitutecoreStrategic or Co-development PartnerTETEC emerged as spin-off from the Natural and Medical Sciences Institute in 2000. Continues to maintain close collaborations with this local innovation hub. Joint research and development activities in tissue engineering and cell therapy.
• University of TübingencoreStrategic or Co-development PartnerResearch partnership rooted in TETEC's origin story as spin-off from Berufsgenossenschaftliche Unfallklinik Tübingen. Ongoing clinical research collaborations and university partnerships for cartilage regeneration development.
• BioRegio STERNminorStrategic or Co-development PartnerTETEC is part of the BioRegio STERN biotech network, which includes 120 medtech companies and 110 biotech companies. Network provides innovation ecosystem and collaborative opportunities in the Stuttgart/Tübingen region.
• Aesculap Biologics, LLCcoreStrategic or Co-development PartnerPart of the same orthobiologics acquisition as TETEC by Octane Medical Group. Aesculap Biologics LLC in the United States and TETEC AG in Germany together form the orthobiologics platform acquired from B. Braun, including NOVOCART product portfolio.
• Cocoon Bioreactor (Octane)coreTechnology or IntegrationOctane's proprietary automated cell production system. TETEC plans to integrate Cocoon for transitioning from current manual production to full automation. This first-of-its-kind automated production system for personalized cell therapies enables precise control and scalability.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Zimmer Biomet: Zimmer Biomet offers orthobiologics including DeNovo NT and cartilage repair technologies within a large joint reconstruction franchise. Comparable broad incumbent operating in the same cartilage/sports medicine clinical workflows as TETEC.
• Arthrex: Arthrex is a major orthopedics and sports medicine device company with cartilage and biologics offerings. Comparable as a broad incumbent serving the same orthopedic surgeon channel through which TETEC sells NOVOCART.
• Smith+Nephew: Smith+Nephew sells cartilage repair and orthobiologics products (e.g., CartiKit, REGENETEN) alongside a broad sports medicine portfolio. Comparable broad incumbent whose portfolio overlaps with TETEC's cartilage regeneration focus.
• Stryker Corporation: Stryker operates a major orthopedics franchise with sports medicine and cartilage-related products. Comparable broad incumbent competing for the same hospital procurement budgets and surgeon mindshare as TETEC.

Emerging players

• LifeNet Health: LifeNet Health provides allograft and orthobiologics solutions, including cartilage allografts, for orthopedic surgeons. Comparable as an emerging orthobiologics competitor offering off-the-shelf alternatives to autologous chondrocyte transplantation.
• Medipost Co., Ltd. Medipost markets Cartistem, an allogeneic umbilical cord blood MSC product for cartilage regeneration. Comparable emerging alternative modality directly competing for the same cartilage defect indication with an off-the-shelf delivery model.
• Cook Medical: Cook Medical's regenerative medicine arm includes orthobiologics and cartilage repair devices. Comparable as a focused orthobiologics player with overlap in the cartilage repair and sports medicine surgeon channel.

Others

• Lonza Group: Lonza is a leading global CDMO with significant cell and gene therapy manufacturing capacity. Comparable to TETEC's CDMO arm (now Octane CDMO) as an adjacent ATMP contract manufacturing service provider rather than a direct product competitor.

Direct peers

• Geistlich Pharma: Geistlich manufactures Chondro-Gide, a collagen matrix widely used in matrix-associated chondrocyte transplantation. Comparable as a scaffold-supplier partner/competitor whose matrix technology can be paired with autologous chondrocytes similar to NOVOCART 3D.
• Vericel Corporation: Vericel develops and markets MACI, an autologous cultured chondrocyte product for cartilage defect repair. Direct competitor to TETEC's NOVOCART franchise, with EU centralized approval already in hand - the most relevant comparable in autologous cartilage cell therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tetec-tissue-engineering-technologies-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TETEC AG